ISRCTN14593637已完成2 期
Randomised controlled crossover trial of Inhaled Furosemide for Dyspnoea relief in advanced Heart Failure
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant is willing and able to give informed consent for participation in the trial
- •2. Male or female, aged 18 years or above (there is no upper age limit although the investigator will ensure they have the capacity to understand, consent and have the ability to perform the studies required)
- •3. Diagnosed with heart failure more than 3 months ago
- •4. Diagnosed with heart failure with a documented reduced ejection fraction <40%
- •5. Significant breathlessness that limits what they are able to do. MRC Dyspnoea Scale =2
- •6. In the Investigator’s opinion, is able and willing to comply with all trial requirements
- •7. Female participants of childbearing potential must be willing to ensure that they use effective contraception during the period they are taking the IMP/placebo and for 48 hours after Visit 5
- •8. Prescribed regular furosemide or bumetanide tablets for at least 1 month
排除标准
- •1. Those unable to consent for themselves
- •2. History of allergic reaction (hypersensitive) to furosemide and/or any of the other ingredients of furosemide or amiloride, sulfonamides or sulphonamide derivatives, such as sulfadiazine or co-trimoxazole
- •3. Unplanned heart failure related hospital admission within the last month (unstable heart failure).
- •4. Patients diagnosed with heart failure within the last 3 months (unstable heart failure)
- •5. Individuals who are dehydrated or have significant symptomatic postural hypotension
- •6. Significant renal impairment (eGFR < 15) or anuric
- •7. Potassium < 3.0 or > 5.9 or Sodium < 130 or > 150 over the preceding month prior the screening visit.
- •8. Significant hepatic impairment/cirrhosis (Child-Pugh class C)
- •9. Addison's disease
- •10. Digitalis intoxication
- •11. Porphyria
- •12. Individuals who are immunocompromised
- •13. Patient with life expectancy < 6 months
- •14. Co-existent history of significant chronic obstructive pulmonary disease or asthma or interstitial lung disease or nasal polyps
- •15. Patients on inhaled B2 agonist therapy
- •16. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patients at risk because of participation in the trial, or may influence the result of the trial, or the patient’s ability to participate in the trial
- •17. Have participated in another research trial involving investigational product in the past 4 weeks
- •18. Female patients who are pregnant, lactating or planning pregnancy over the course of trial
研究者
相似试验
进行中（未招募）
1 期
A clinical trial into the relief of breathlessness in patients with heart failure by inhaling furosemide which is usually taken as a tablet or injection.Advanced heart failure with reduced ejection fraction (less than or equal to 40%) with significant breathlessness that limits what they are able to do. MRC Dyspnoea Scale =2.MedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2017-000124-95-GBniversity of Oxford30
进行中（未招募）
不适用
Clinical trial of Flecainide for Catecholaminergic Ventricular TachycardiaPatients with CPVT and ICDMedDRA version: 14.1Level: LLTClassification code 10028159Term: Multiform ventricular tachycardiaSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001287-22-ITFONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
尚未招募
不适用
A clinical trial to compare two different treatment modalities for treating nausea and/or vomiting in the emergencyCTRI/2020/03/024122Mohanapriya V S
进行中（未招募）
不适用
Randomized controlled trial of the efficacy of fosfomycin vs ciprofloxacin as antibiotic prophylaxis before transrectal ultrasound guided prostateurinary sepsisEUCTR2012-001031-31-ESFundación para Formación e Investigación Sanitaria
已完成
3 期
Multicentre, randomized controlled trial of the Frankfurt Early Intervention Program for tod-dlers and preschool children with Autism Spectrum Disorder – A-FFIPDSM-5: 299.0 Autism Spectrum DisorderF84.0F84.5Childhood autismAsperger syndromeDRKS00016330Goethe Universität Frankfurt am Main134